GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MediciNova Inc (TSE:4875) » Definitions » Total Liabilities

MediciNova (TSE:4875) Total Liabilities : 円458.9 Mil (As of Mar. 2024)


View and export this data going back to 2005. Start your Free Trial

What is MediciNova Total Liabilities?

MediciNova's Total Liabilities for the quarter that ended in Mar. 2024 was 円458.9 Mil.

MediciNova's quarterly Total Liabilities increased from Sep. 2023 (円512.58 Mil) to Dec. 2023 (円560.38 Mil) but then declined from Dec. 2023 (円560.38 Mil) to Mar. 2024 (円458.89 Mil).

MediciNova's annual Total Liabilities increased from Dec. 2021 (円424.48 Mil) to Dec. 2022 (円527.92 Mil) and increased from Dec. 2022 (円527.92 Mil) to Dec. 2023 (円560.38 Mil).


MediciNova Total Liabilities Historical Data

The historical data trend for MediciNova's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MediciNova Total Liabilities Chart

MediciNova Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 470.33 424.83 424.48 527.92 560.38

MediciNova Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 455.39 500.83 512.58 560.38 458.89

MediciNova Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

MediciNova's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=472.115+(0+59.177
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+29.084+0)
=560.4

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=9541.654-8981.278
=560.4

MediciNova's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=376.045+(0+52.586
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+30.263+0)
=458.9

Total Liabilities=Total Assets (Q: Mar. 2024 )-Total Equity (Q: Mar. 2024 )
=9422.691-8963.647
=459.0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MediciNova Total Liabilities Related Terms

Thank you for viewing the detailed overview of MediciNova's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


MediciNova (TSE:4875) Business Description

Traded in Other Exchanges
Address
4275 Executive Square, Suite 300, La Jolla, CA, USA, 92037
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.

MediciNova (TSE:4875) Headlines

No Headlines